FIRST AMENDMENT TO COMPOUND LICENSE AGREEMENT FOR APG1197Compound License Agreement • November 25th, 2019 • Unity Biotechnology, Inc. • Pharmaceutical preparations
This Amendment (the “Amendment”), dated as of November 19, 2019 (the “Amendment Effective Date”) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (“Ascentage”), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 3280 Bayshore Blvd, Suite 100, Brisbane, California 95002. Ascentage and Unity are sometimes referred to herein as individually as a “Party” and collectively as the “Parties”.
Compound License Agreement for APG1197Compound License Agreement • March 6th, 2019 • Unity Biotechnology, Inc. • Pharmaceutical preparations • New York
This Compound License Agreement (the “Agreement”) effective as of the 2nd day of January, 2019, (the “Effective Date”) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation and its affiliates (collectively, “Ascentage”), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 3280 Bayshore Blvd, Suite 100, Brisbane, California 94005. Each of Ascentage and Unity shall be a “Party,” and both the “Parties.”
SECOND AMENDMENT TO COMPOUND LICENSE AGREEMENT FOR APG-1197Compound License Agreement • March 11th, 2020 • Unity Biotechnology, Inc. • Pharmaceutical preparations
This second amendment (the “Second Amendment”), dated as of January 8, 2020 (the “Amendment Effective Date”) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (“Ascentage”), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 3280 Bayshore Blvd, Suite 100, Brisbane, California 95002. Ascentage and Unity are sometimes referred to herein as individually as a “Party” and collectively as the “Parties.”
THIRD AMENDMENT TO COMPOUND LICENSE AGREEMENT FOR APG-1197Compound License Agreement • July 1st, 2020 • Unity Biotechnology, Inc. • Pharmaceutical preparations
This third amendment (the “Third Amendment”) to the Compound License Agreement for APG1197 dated January 2, 2019 (the “Original License Agreement”) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (“Ascentage”), with a business address at 9/F, Wah Yuen Building 149 Queen’s Road , Central Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 285 East Grand Avenue, South San Francisco, California 94080 effective as of June 29, 2020 (the “Third Amendment Effective Date”). Ascentage and Unity are sometimes referred to herein as individually as a “Party” and collectively as the “Parties”. Defined terms used herein and not otherwise defined shall have the meanings set forth in the Original License Agreement.
